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Background: Coronary artery disease (CAD) is the most frequent cause of morbidity and mortality in the
world and it is known as a multifactorial disorder which is influenced by both genetic and environmental
factors. Based on different assays, the platelet derived growth factor B (PDGF-B) gene is shown to be
amongst the inflammation inducers involved in different pathological conditions such as atherosclerosis.
Aim: In this case-control study we have examined the association of the functional PDGF-B +286 and
+1135 polymorphisms and its expression status with susceptibility to CAD.
Subjects and methods: Study groups included 369 patients with CAD and 413 healthy individuals.
Genotypic and allelic frequencies of PDGF-B +286 and +1135 polymorphisms were determined by the
SSP-PCR method. PDGF-B expression status was identified by quantitative real-time PCR.
Results: The analysis of genotyping results revealed CAD patients had an increased frequency of PDGF-B
+286A>G A/A genotype in comparison with healthy individuals. Furthermore, we found that the PDGF-B
expression level in CAD patients group is nearly 2-folds greater than its level in control group.
Conclusion: There is probably a relationship between variations in PDGF-B gene and CAD influence. The
increase in PDGF-B gene expression may has a role in susceptibility to CAD.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD) is the most frequent cause of dis-
ability and the world’s major cause of death. The CAD is a complex
chronic multifactorial disorder that results from obvious genetic
susceptibility and environmental risk factors and their interactions
[1] and starts during adolescence and slowly progressing during
life. Family history is regarded as one of the important autonomous
CAD risk factors, and identifying the susceptibility genes for this
frequent and complex disease, is a crucial goal [2]. CAD is defined
as narrowing of epicardial coronary arteries induced by a build-up
of atherosclerotic plaques. Inflammation is considered as one of the
main processes contributing to atherogenesis [3]. According to
National Heart, Lung, and Blood Institute in 2010 the prevalence
of CAD was lower in women with age <60 years than men with
same age. The CAD rate increases in both genders after age60 years, especially in men who are living in the ’80 s [4]. Among
the different risk factors associated with CAD, age, gender, cigar-
ette smoking, hypertension and hyperlipidemia are more effective.
The manifestation of fibrous atherosclerotic plaque results from
modification or acceleration of multiple inflammatory-fibro prolif-
erative responses. The risk factors and the vascular smooth muscle
cells are the central cell component involved in these responses.
CAD is approximately 40–60% heritable, but its genetics mecha-
nism is not completely clear. Genetics-epidemiological and twin
studies have revealed the role of genetics factors in the atheroscle-
rosis development. Moreover, case-control studies on polymor-
phisms have identified genes associated with increased risks to
CAD [5,6].
The Platelet derived growth factor B (PDGF-B) gene locus is
located on 22q13.1 chromosome, producing a cationic hydrophilic
30 KD protein which binds to specific receptors, and now is consid-
ered as one of the best characterized growth factor-receptor sys-
tems. PDGF-B was described approximately 40 years ago as a
potent mitogen and chemo-attractant serum factor, and was eli-
cited from the alpha-granules of the platelets. This protein stimu-
lates the proliferation of mesenchymal original cells such as
fibroblasts and vascular smooth muscle cells. Different assays have
360 S. Rezayani et al. / The Egyptian Journal of Medical Human Genetics 18 (2017) 359–363shown that PDGF contributes to different pathological conditions
such as atherosclerosis, fibrosis, restenosis, glomerulonephritis,
liver cirrhosis, pulmonary fibrosis and cancer. The conventional
PDGF-A and PDGF-B, and more recently discovered PDGF-C and
PDGF-D polypeptides, constitute four members of PDGF family
[7,8]. Four disulfide-bonded homodimers of PDGF protein includ-
ing PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD, and one heterodi-
mer, PDGF-AB are biologically active proteins. These proteins act
through structural activation of two tyrosine kinase receptors,
PDGFRa and PDGFRb [9,10]. PDGF is expressed by cells which
related to mesenchymal cells expressed PDGF receptors, including
megakaryocytes that are the precursor of platelets cells. These
expressional patterns suggest that PDGF mediates paracrine sig-
naling. Although some recent case-control studies have been per-
formed on gene polymorphisms in CAD at populations with
different geographic and genetic diversity [5,6]. No studies have
been examined the role of these PDGF-B functional polymorphisms
in susceptibility to CAD in Iranian population yet. Therefore, we
conducted a case-control study to analyze the association of the
PDGF-B functional polymorphisms (positions of +286 and +1135
from transcription start site) and PDGF-B expression level with sus-
ceptibility to CAD in Iranian population.2. Subjects and methods
2.1. Study subjects
In this prospective study, we randomly screened 369 CAD
patients and 413 control individuals (mean age 30–60) from the
northeast of Iran to analyze the genetic variations in the PDGF-B
gene +286 and +1135 loci. For selecting the CAD patients, two
expert cardiologists confirmed the occurrence of CAD, according
the clinical and paraclinical findings, invasive angiography, as
70% stenosis in at least 1 major epicardial coronary artery. Con-
trol subjects were selected randomly among healthy individuals
with a normal angiography (15% stenosis) and with no visible
autoimmune or inflammatory disorders. This work has been car-
ried out in accordance with the Code of Ethics of theWorld Medical
Association (Declaration of Helsinki) for experiments in humans,
and was approved by the local Ethical Committee. The informed
written consent was obtained from all recruited individuals. None
of the approached subjects refused to participate. Expression assay
also was randomly performed on 80 CAD patients and 80 control
individuals among the same individuals with the same age
condition.2.2. DNA extraction and genotyping
Genomic DNA was extracted from 2 ml peripheral whole blood
by a standard protocol [11]. Briefly, red blood cells were lysed
three times with a buffer containing ammonium chloride, potas-
sium dihydrogen phosphate, and disodium hydrogen phosphates
(Sigma, Munich, Germany). Then, SDS (10%), EDTA, and 10 ll pro-
teinase K (Sigma, Munich, Germany) were added to the pellet that
was incubated for 1 h at 65 C. After incubation, a phenol/chloro-
form/isoamyl alcohol mix (Sigma, Munich, Germany) was added
to samples. The mix was then centrifuged. Isopropanol and sodium
acetate (Merck, Kenilworth, US) were added to the supernatant to
visualize and precipitate the DNA, and DNA was extracted after
centrifugation. Using a spectrophotometer (Techne, Staffordshire,
UK), the amount of DNA for each sample was determined by
measuring the optical density at 260 nmwavelength. DNA samples
were aliquoted in graded distilled water and stored at 80 C until
used. The sequence-specific primer-polymerase chain reaction
(SSP-PCR) method was used for genotyping. To detect thePDGF-B polymorphism at +286 and +1135 position, 100 ng of
genomic DNA was amplified in a 15 ml reaction mix with 13 ll
master mix containing 20 lm dNTP, 1X ready-load PCR buffer,
DMSO, one unit Taq polymerase (GENETBIO, Daejeon, South
Korea), 6 lm human growth hormone primer (Eurofins, Ebersberg,
Germany) as internal control, and 30 lM of each specific primer
(Eurofins, Ebersberg, Germany). The PCR reaction for SNPs of
+286 and +1135 were performed in a Thermal Cycler (Techne,
Staffordshire, UK), with the one program that described previously
[12]. The primer sequences used for both polymorphisms are
shown in Table 1. The PCR products were electrophoresed on a
1.5% agarose gel (Merck, Germany), and bands were visualized
with a gel documentation system (Uvitec, Cambridge, UK).
2.3. Quantitative real-time PCR
Total RNA was extracted from cultured leukocytes of 6 ml of
peripheral whole blood. The transcriptor First Strand cDNA Synthe-
sis Kit (Roche, Grenzach-Wyhlen, Germany) was used to convert-
ing 1 lg of total RNA into cDNA. Quantitative real-time
polymerase chain reaction of the PDGF-B gene was performed in
duplicates in ABI Prism 7300 Sequence Detection System using
SYBR Green (Applied Biosystems, Foster City, US) according to
the manufacturer’s instructions with the following optimized PCR
conditions (94 C 10 min, and 94 C 30 s, 58 C 1 min, 72 C 45 s
for 35 cycles, then 10 min extension at 72 C). All thresholds cycle
(Ct) of PDGF-B gene normalized with PGK1 cDNA. The used pri-
mers are shown in Table 1. Primers were designed based on
sequences from the GenBank and to span exon-intron junctions
to prevent amplification of genomic DNA. The mRNA level was cal-
culated using the 2-DCt method [13].
2.4. Statistical analysis
After entering data in a SPSS v-16 program, the means of para-
metric variables were calculated. Data are presented as Mean ± SD
for parametric variables and as percentages for non-parametric
values. Allele and genotype frequencies were calculated and com-
pared between groups by non-parametric tests followed by Fish-
er’s exact analysis using STATA v-8 (CA, US). P-values were
determined, and those less than 0.05 were considered to be
significant.3. Results
A total of 369 CAD patients and 413 healthy individuals were
successfully genotyped for SNPs, PDGF-B +286A>G and PDGF-B
+1135A>C. In both SNPs, deviation from the Hardy-Weinberg equa-
tion was not observed in either patient group (PDGF-B +286A>G:
v2 = 0.263, df = 1, p = 0. 607 and PDGF-B +1135A>C: v2 = 0.119,
df = 1, p = 0. 730), or the control group (PDGF-B +286A>G:
v2 = 0.096, df = 1, p = 0.765 and PDGF-B +1135A>C: v2 = 0.864,
df = 1, p = 0.352). Complementary data including the allele and
genotype frequencies of PDGF-B +286 are shown in Table 2.
According to the data analysis, there is a significant association
between A/A genotype and CAD disease [OR (95%CI): 1.58 (1.05–
2.36), p = 0.032]. The results also indicated that allele A is signifi-
cantly associated with the CAD disease [OR (95%CI): 1.26 (1.03–
1.54), p = 0.021]. As the Table 3 showed, allelic and genotypic fre-
quencies of PDGF-B +1135 polymorphism did not show any signif-
icant statistical association with CAD. To investigate the
inheritance model of SNPs at PDGF-B gene, three models of reces-
sive, dominant and co-dominant were considered and no signifi-
cant association was seen in inheritance models, in both SNPs
(Tables 2 and 3). Combined genotypes distribution of PDGF-B
Table 1
The used primers in this study.
Amplified factor Primers 50–30 Bond size (bp) Annealing temperature (C) Genbank Accession
Number
SSP-PCR
PDGF-B (+286) Forward-A GCCCAGAGCGGCGAGCA 235 57 NG_012111
Forward-G GCCCAGAGCGGCGAGCG
Reverse TTCCAAAGTTGGCTTTGCAAC
PDGF-B (+1135) Forward-A ATTCATTACCTTCGCCCCCA 263 55
Forward-C ATTCATTACCTTCGCCCCCC
Reverse TGTTCTCGGGTTCCCAAAGG
hGH-N Forward GCCTTCCCAACCATTCCCTTA 429 50 NG_011676.1
Reverse TCACGGATTTCTGTTGTG
Real-Time PCR
PDGF-B Forward AGTGGCCAAATAGGAGGGAG 81 54 NM_002608.3
Reverse AGGACTTTGGGAAATGGAGG
PGK1 Forward GCAGATTGTGTGGAATGGTC 101 53 NM_000291.3
Reverse CCCTAGAAGTGGCTTTCACC
Table 2
The genotypic and allelic distribution of PDGF-B +286 A>G polymorphism in CAD and control group.
Characteristic Patients, n (%) Control, n (%) OR (95% CI) p value
Genotypes
G/G 65 (17.6) 94 (22.8) 1 –
A/G 174 (47.2) 200 (48.4) 1.25 (0.86–1.83) 0.253
A/A 130 (35.2) 119 (28.8) 1.58 (1.05–2.36) 0.032
Alleles
G 304 (41.2) 388 (47) 1 –
A 434 (58.8) 438 (53) 1.26 (1.03–1.54) 0.021
Model of inheritance
Recessive (A/A vs. G/G + A/G) 0.74 (0.55–1.00) 0.055
Dominant (A/G + A/A vs. G/G) 1.37 (0.96–1.96) 0.075
Co-dominant (A/G vs. G/G + A/A) 1.05 (0.79–1.39) 0.774
OR, odds ratio; CI, confidence interval; Significant p values are bold.
Table 3
The genotypic and allelic distribution of PDGF-B +1135 A>C polymorphism in CAD and control group.
Characteristic Patients, n (%) Control, n (%) OR (95% CI) p value
Genotypes
A/A 164 (44.4) 186 (45.0) 1 –
A/C 162 (43.9) 176 (42.6) 1.04 (0.77–1.40) 0.818
C/C 43 (11.7) 51 (12.3) 0.95 (0.60–1.51) 0.907
Alleles
A 490 (66.4) 548 (53.2) 1 –
C 248 (33.6) 278 (46.8) 0.99 (0.80–1.23) 1.000
Model of inheritance
Recessive (C/C vs. A/A + A/C) 1.06 (0.69–1.64) 0.825
Dominant (A/C + C/C vs. A/A) 1.02 (0.77–1.35) 0.885
Co-dominant (A/C vs. A/A + C/C) 0.94 (0.71–1.26) 0.718
OR, odds ratio; CI, confidence interval.
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been shown in Table 4, and analysis results indicated that there is
no significant association between combinations of genotypes with
the CAD in this population.
In order to compare the PDGF-B mRNA level in patient and con-
trol groups, we used a relative RT-PCR assay on PDGF-B cDNA sam-
ples. Our results have shown, averages of PDGF-B level in CAD
group (4.11 ± 1.41) was significantly higher in comparison with
healthy group (2.01 ± 0.94) (p = 0.011) (Fig. 1).
4. Discussion
Despite the remarkable successes in identification of genetics
variants that affect common risk factors, such as cholesterol levels,the progress in exploration of novel CAD genes has been slow.
Some recent findings emphasize a relationship between CAD and
inflammation [14] and PDGF-B as an important inducer and mod-
ulator factor of inflammation, contributes to atherosclerosis occur-
rence. Despite the fact that the platelets are the basic origin of the
PDGFs, the expression of these growth factors is induced in all the
constituent cells of normal vessel wall and inflammatory cells, and
this induction is in response to penetration of the pathological
stimuli into the vessels. The Acute vascular injuries show increased
release of PDGFs from the vascular cells such as the endothelial
cells, vascular smooth muscle cells, active monocytes and mono-
cyte derived macrophages [15–17]. Moreover, the increased
expression of PDGF-B mRNA has been reported several times in
atherosclerotic plaques in humans [18]. These studies have also
Table 4
Combined genotypes distribution of PDGF-B +286 and +1135 polymorphisms in control and patient groups.
Combined genotypes
(PDGF + 1135/+286)
Case
n (%)
Control
n (%)
OR (CI 95%) P value
AA/GG 32 (7.8) 22 (6) 1 –
AA/AA 66 (16) 68 (18.4) 1.49 (0.75 – 3.00) 0.259
AA/AG 88 (21.3) 74 (20.1) 1.22 (0.62–2.41) 0.635
CC/AA 10 (2.4) 8 (2.2) 1.16 (0.33 – 3.87) 0.780
CC/GG 20 (4.8) 19 (5.1) 1.38 (0.55 – 5.43) 0.520
CC/AG 21 (5.1) 16 (4.3) 1.10 (0.43 – 2.80) 0.830
AC/AA 43 (10.4) 54 (14.6) 1.82 (0.88 – 3.80) 0.091
AC/GC 42 (10.2) 24 (6.5) 0.83 (0.37 – 1.86) 0.710
AC/AG 91 (22) 84 (22.8) 1.34 (0.69 – 2.62) 0.431
OR, odds ratio; CI, confidence interval.
Fig. 1. QRT-PCR analysis of PDGF-B mRNA. The cDNA levels of genes were
normalized to PGK1 cDNA. The PDGF-B expression level in patients group was
significantly higher than healthy group.
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observations directly evidence the contribution of the PDGF in
atherogenesis. However, to the best of our knowledge, the present
study is the first document on analysis of the PDGF-B expression in
PBMCs of CAD patients. Our results showed that PDGF-B gene tran-
scripts were elevated in PBMCs of CAD patients nearly 2-folds than
normal individuals. In this study, a statistically significant differ-
ence was noted in the distribution of the PDGF-B polymorphism
at position +286 between the case and control groups. This result
is consistent with an earlier study by Tambur et al. [19] that had
analyzed PDGF-B +286A>G and +1135A>C polymorphisms in heart
transplant recipients who showed CAD after angiography. They
also found a significant difference in A/A genotype in +286A>G
position between patients and controls, and suggested that this
SNP may play an important role in susceptibility of CAD. Further-
more, in contrast to our work, they found a significant difference
in C/C genotype in +1135A>C SNP between patients and controls.
Few recent studies have documented the expression of PDGF-B
in plasma and the atherosclerotic lesions separated from coronary
vessel wall autopsies of CAD patients. Rinse et al. [18] in their
study showed that PDGF-B mRNA expression in atherosclerotic
lesions is higher than in normal vessel walls. In another study Bar-
rett et al. [15] studied the expression level of PDGF-B mRNA in
atherosclerotic plaques and normal vessel walls. Their finding
showed more than 5-folds increase in mRNA transcripts. The pro-
liferation of smooth muscle cells (SMC), as the most frequent
atherosclerotic forming cells, is the basic aspect in progression of
the human atherosclerotic lesions. Moreover, cellular response of
the human vessel walls after angioplasty is often performed by
SMCs. The SMC proliferation and migration controlling factors
are key elements in progress of these lesions. Laboratory
researches have shown that PDGFs are one of the biological deter-
minants involved in this process [15,20]. Tanizawa et al. study [20]
examined PDGF-B expression of eight patients with coronary arter-
ies who had died after angioplasty due to heart ischemia. Theirfindings showed that there is a PDGF mediated repair process with
involvement of SMCs and macrophages. In another study, Ueda
et al. [21] examined the presence of PDGF-B mRNAs in coronary
artery autopsies after angiography. Their results showed that in
humans the B chain of PDGF gene is expressed in injury sites and
in connection with reconstructive processes. Cagnin et al. study
[22] investigated the expressional changes of human carotid genes
influenced by atherosclerotic plaques. They found an increased
level of PDGF-B in plasma of atherosclerosis patients. Tuuminen
et al. study [23] has also shown an increased expression in PDGF-
B in agreement with our findings.
In conclusion, there is probably a relationship between some
PDGF-B functional polymorphisms and CAD influence. The increase
in PDGF-B gene expression may be a risk factor in susceptibility to
CAD. However, in large populations with different ethnic composi-
tion, acquired results may be different.Compliance with ethical standards
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